single10MG
Retatrutide
10MG Protocol
Retatrutide 10MG
Injection Freq.
Inject once weekly
Cycle Sched.
Minimum 24 weeks; trials extended to 48 weeks
Reconstitution
1.0 mL BAC water
Exceptional weight loss reported in trials (~22–24% mean at 48 weeks at higher doses)
HbA1c reduction (~1.3–2.0%) with high rates reaching HbA1c ≤6.5%
Reduced blood pressure, LDL, waist circumference
liver-fat reduction signals
Universal ≥5% responder rate reported at higher doses
1
Reconstitution Requirements
- 1.0 mL BAC water
Escalation steps: 4
Defined through week 12
| Step | Week Range | Dose | Units |
|---|---|---|---|
| 1 | Weeks 1–4 | 2 mg (2000 mcg) | 20 |
| 2 | Weeks 5–8 | 4 mg (4000 mcg) | 40 |
| 3 | Weeks 9–12 | 6 mg (6000 mcg) | 60 |
| 4 | Weeks 1+ | 8 mg (8000 mcg) | 80 |
Inject once weekly
Minimum 24 weeks; trials extended to 48 weeks
The retatrutide (Retatrutide) 10 mg protocol describes a triple-incretin approach that pairs appetite suppression with increased energy expenditure. The page explains that GLP-1 and GIP activation improves glucose-dependent insulin secretion and reduces appetite, while glucagon receptor agonism increases metabolic rate and promotes lipid oxidation. This three-receptor design is presented as producing stronger weight-loss effects than single- or dual-agonist incretin therapies and as countering the metabolic adaptation that can slow weight loss over time. To support convenient use, the molecule includes a fatty-acid moiety that extends its half-life to about 6 days, enabling once-weekly dosing. The protocol summarizes clinical outcomes showing large average reductions in body weight and meaningful HbA1c decreases, alongside improvements in blood pressure, LDL cholesterol, waist circumference, and liver fat in higher-dose cohorts. The main side effects described are dose-dependent gastrointestinal symptoms during titration, with gradual escalation reducing discomfort.
Nausea
Vomiting
Diarrhea
Dose-dependent, transient GI symptoms (most common during escalation)
No severe hypoglycemia or serious treatment-related adverse events reported in cited trials
- Use aseptic technique: wipe vial stopper with alcohol; use new sterile syringe/needle
- Add diluent slowly down the vial wall to minimize foaming
- Gently swirl/roll until fully dissolved (do not shake)
- Label vial with reconstitution date and concentration; protect from light
- Refrigerate after reconstitution (commonly 2–8 °C) unless protocol states otherwise
- Avoid repeated freeze–thaw cycles
- Bacteriostatic Water for Injection contains benzyl alcohol preservative (multi-dose); follow protocol for beyond-use (many peptide protocols use ~28 days after mixing)
- Avoid benzyl-alcohol-containing diluents in neonates/infants (safety warning for benzyl alcohol)